379 related articles for article (PubMed ID: 30552025)
41. DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant.
Menon V; Ayala VI; Rangaswamy SP; Kalisz I; Whitney S; Galmin L; Ashraf A; LaBranche C; Montefiori D; Petrovsky N; Kalyanaraman VS; Pal R
J Gen Virol; 2017 Aug; 98(8):2143-2155. PubMed ID: 28758637
[TBL] [Abstract][Full Text] [Related]
42. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
[TBL] [Abstract][Full Text] [Related]
43. Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin.
Ringe RP; Cruz Portillo VM; Dosenovic P; Ketas TJ; Ozorowski G; Nogal B; Perez L; LaBranche CC; Lim J; Francomano E; Wilson IA; Sanders RW; Ward AB; Montefiori DC; Nussenzweig MC; Klasse PJ; Cupo A; Moore JP
J Virol; 2020 Feb; 94(6):. PubMed ID: 31852794
[TBL] [Abstract][Full Text] [Related]
44. Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.
Willey R; Nason MC; Nishimura Y; Follmann DA; Martin MA
AIDS Res Hum Retroviruses; 2010 Jan; 26(1):89-98. PubMed ID: 20059398
[TBL] [Abstract][Full Text] [Related]
45. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.
Parren PW; Marx PA; Hessell AJ; Luckay A; Harouse J; Cheng-Mayer C; Moore JP; Burton DR
J Virol; 2001 Sep; 75(17):8340-7. PubMed ID: 11483779
[TBL] [Abstract][Full Text] [Related]
46. Post-infection immunodeficiency virus control by neutralizing antibodies.
Yamamoto H; Kawada M; Takeda A; Igarashi H; Matano T
PLoS One; 2007 Jun; 2(6):e540. PubMed ID: 17579714
[TBL] [Abstract][Full Text] [Related]
47. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
[TBL] [Abstract][Full Text] [Related]
48. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
49. Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus.
Himeno A; Ishida Y; Mori H; Matsuura K; Kikukawa M; Sakawaki H; Miura T
Arch Virol; 2019 May; 164(5):1297-1308. PubMed ID: 30820667
[TBL] [Abstract][Full Text] [Related]
50. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4.
Robinson JE; Franco K; Elliott DH; Maher MJ; Reyna A; Montefiori DC; Zolla-Pazner S; Gorny MK; Kraft Z; Stamatatos L
J Virol; 2010 Apr; 84(7):3443-53. PubMed ID: 20106929
[TBL] [Abstract][Full Text] [Related]
51. Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site.
Bradley T; Fera D; Bhiman J; Eslamizar L; Lu X; Anasti K; Zhang R; Sutherland LL; Scearce RM; Bowman CM; Stolarchuk C; Lloyd KE; Parks R; Eaton A; Foulger A; Nie X; Karim SSA; Barnett S; Kelsoe G; Kepler TB; Alam SM; Montefiori DC; Moody MA; Liao HX; Morris L; Santra S; Harrison SC; Haynes BF
Cell Rep; 2016 Jan; 14(1):43-54. PubMed ID: 26725118
[TBL] [Abstract][Full Text] [Related]
52. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT
J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574
[TBL] [Abstract][Full Text] [Related]
53. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
[TBL] [Abstract][Full Text] [Related]
54. Effects of virus burden and chemokine expression on immunity to SHIV in nonhuman primates.
Waterman PM; Kitabwalla M; Hatfield GS; Evans PS; Lu Y; Tikhonov I; Bryant JL; Pauza CD
Viral Immunol; 2004; 17(4):545-57. PubMed ID: 15671751
[TBL] [Abstract][Full Text] [Related]
55. R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.
Siddappa NB; Watkins JD; Wassermann KJ; Song R; Wang W; Kramer VG; Lakhashe S; Santosuosso M; Poznansky MC; Novembre FJ; Villinger F; Else JG; Montefiori DC; Rasmussen RA; Ruprecht RM
PLoS One; 2010 Jul; 5(7):e11689. PubMed ID: 20657739
[TBL] [Abstract][Full Text] [Related]
56. Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.
Dennis M; Eudailey J; Pollara J; McMillan AS; Cronin KD; Saha PT; Curtis AD; Hudgens MG; Fouda GG; Ferrari G; Alam M; Van Rompay KKA; De Paris K; Permar S; Shen X
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541851
[TBL] [Abstract][Full Text] [Related]
57. Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates.
Cai F; Chen WH; Wu W; Jones JA; Choe M; Gohain N; Shen X; LaBranche C; Eaton A; Sutherland L; Lee EM; Hernandez GE; Wu NR; Scearce R; Seaman MS; Moody MA; Santra S; Wiehe K; Tomaras GD; Wagh K; Korber B; Bonsignori M; Montefiori DC; Haynes BF; de Val N; Joyce MG; Saunders KO
PLoS Pathog; 2021 Jun; 17(6):e1009624. PubMed ID: 34086838
[TBL] [Abstract][Full Text] [Related]
58. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.
Mooij P; van der Kolk M; Bogers WM; ten Haaft PJ; Van Der Meide P; Almond N; Stott J; Deschamps M; Labbe D; Momin P; Voss G; Von Hoegen P; Bruck C; Heeney JL
AIDS; 1998 Mar; 12(5):F15-22. PubMed ID: 9543435
[TBL] [Abstract][Full Text] [Related]
59. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M
J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693
[TBL] [Abstract][Full Text] [Related]
60. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
